2-Methoxyestradiol and Disorders of Female Reproductive Tissues

Hormones and Cancer

Volumn 5, Issue 5, 2014, Pages 274-283

  Pinto, Mauricio P ^a   Medina, Rodolfo A ^b   Owen, Gareth I ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ESTROGEN RECEPTOR; 2-METHOXYESTRADIOL; ESTRADIOL; ESTROGEN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER THERAPY; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SOLUBILITY; ESTROGEN METABOLISM; GYNECOLOGIC DISEASE; HUMAN; MICROTUBULE; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; FEMALE; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGENS; FEMALE; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 84907086979     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0181-2     Document Type: Review

References (98)

1. Aranda E, Owen GI (2009) A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line. Biol Res 42(3):377–389
2. Ashton KA, Meldrum CJ, McPhillips ML, Suchy J, Kurzawski G, Lubinski J, Scott RJ (2006) The association of the COMT V158M polymorphism with endometrial/ovarian cancer in HNPCC families adhering to the Amsterdam criteria. Hered Cancer Clin Pract 4(2):94–102. doi:10.1186/1897-4287-4-2-94
3. Barnes CM, McElrath TF, Folkman J, Hansen AR (2010) Correlation of 2-methoxyestradiol levels in cord blood and complications of prematurity. Pediatr Res 67(5):545–550. doi:10.1203/PDR.0b013e3181d4efef
4. Basini G, Bussolati S, Santini SE, Bianchi F, Careri M, Mangia A, Musci M, Grasselli F (2007) Antiangiogenesis in swine ovarian follicle: a potential role for 2-methoxyestradiol. Steroids 72(8):660–665. doi:10.1016/j.steroids.2007.05.002
5. Basini G, Santini SE, Grasselli F (2006) 2-Methoxyestradiol inhibits superoxide anion generation while it enhances superoxide dismutase activity in swine granulosa cells. Ann N Y Acad Sci 1091:34–40. doi:10.1196/annals.1378.052
6. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, Folkman J, D’Amato RJ (2008) 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 172(2):534–544. doi:10.2353/ajpath.2008.061244
7. Brueggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Joomprabutra S, Weitzel DH, Vandre DD, Yusuf F, Burak WE Jr (2001) 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 78(2):145–156
8. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M (2002) Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 531(2):141–151
9. Bu SZ, Huang Q, Jiang YM, Min HB, Hou Y, Guo ZY, Wei JF, Wang JW, Ni X, Zheng SS (2006) p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis 11(3):413–425. doi:10.1007/s10495-006-4064-z
10. Bulletti C, Coccia ME, Battistoni S, Borini A (2010) Endometriosis and infertility. J Assist Reprod Genet 27(8):441–447. doi:10.1007/s10815-010-9436-1
11. Cho JK, Hong KY, Park JW, Yang HK, Song SC (2011) Injectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel. J Drug Target 19(4):270–280. doi:10.3109/1061186X.2010.499461
12. Choi HJ, Zhu BT (2012) Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol. Biochim Biophys Acta 1823(8):1306–1315. doi:10.1016/j.bbamcr.2012.05.003
13. Chua YS, Chua YL, Hagen T (2010) Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol Cancer Ther 9(1):224–235. doi:10.1158/1535-7163.MCT-09-1003
14. D’Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 91(9):3964–3968
15. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D et al (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1):22–27
16. Day JM, Newman SP, Comninos A, Solomon C, Purohit A, Leese MP, Potter BV, Reed MJ (2003) The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 84(2–3):317–325
17. Du B, Li XT, Zhao Y, You-Mei A, Zhang ZZ (2010) Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie 65(7):471–476
18. Du B, Wang SY, Shi XF, Zhang CF, Zhang ZZ (2011) The effect of 2-methoxyestradiol liposome on growth inhibition, angiogenesis and expression of VEGF and Ki67 in mice bearing H22 hepatocellular carcinoma. Tumori 97(5):660–665. doi:10.1700/989.10728
19. Du B, Zhao Z, Sun H, Ma S, Jin J, Zhang Z (2012) Effects of 2-methoxyestradiol on proliferation, apoptosis and gene expression of cyclin B1 and c-Myc in esophageal carcinoma EC9706 cells. Cell Biochem Funct 30(2):158–165. doi:10.1002/cbf.1830
20. Du L, Merali Z, Poulter MO, Palkovits M, Faludi G, Anisman H (2014) Catechol-O-methyltransferase Val158Met polymorphism and altered COMT gene expression in the prefrontal cortex of suicide brains. Prog Neuropsychopharmacol Biol Psychiatry 50:178–183. doi:10.1016/j.pnpbp.2013.12.016
21. Du S, Zhu L, Du B, Shi X, Zhang Z, Wang S, Zhang C (2012) Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev Ind Pharm 38(4):431–438. doi:10.3109/03639045.2011.609560
22. Dubey RK, Imthurn B, Jackson EK (2007) 2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. Endocrinology 148(9):4125–4127. doi:10.1210/en.2007-0514
23. Ehteda A, Galettis P, Pillai K, Morris DL (2013) Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. BMC Cancer 13:86. doi:10.1186/1471-2407-13-86
24. Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65(19):9021–9028. doi:10.1158/0008-5472.CAN-04-4095
25. Feng Y, Zhao X, Zhou C, Yang L, Liu Y, Bian C, Gou J, Lin X, Wang Z, Zhao X (2013) The associations between the Val158Met in the catechol-O-methyltransferase (COMT) gene and the risk of uterine leiomyoma (ULM). Gene 529(2):296–299. doi:10.1016/j.gene.2013.07.019
26. Fernandez-de-las-Penas C, Penacoba-Puente C, Cigaran-Mendez M, Diaz-Rodriguez L, Rubio-Ruiz B, Arroyo-Morales M (2014) Has catechol-O-methyltransferase genotype (Val158Met) an influence on endocrine, sympathetic nervous and humoral immune systems in women with fibromyalgia syndrome? Clin J Pain 30(3):199–204. doi:10.1097/AJP.0b013e3182928da0
27. Florczak U, Toulany M, Kehlbach R, Peter Rodemann H (2009) 2-Methoxyestradiol-induced radiosensitization is independent of SOD but depends on inhibition of Akt and DNA-PKcs activities. Radiother Oncol 92(3):334–338. doi:10.1016/j.radonc.2009.06.005
28. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368(6468):237–239. doi:10.1038/368237a0
29. Fukui M, Zhu BT (2009) Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol Carcinog 48(1):66–78. doi:10.1002/mc.20458
30. Fussell KC, Udasin RG, Smith PJ, Gallo MA, Laskin JD (2011) Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcinogenesis 32(8):1285–1293. doi:10.1093/carcin/bgr109
31. Gong QF, Liu EH, Xin R, Huang X, Gao N (2011) 2ME and 2OHE2 exhibit growth inhibitory effects and cell cycle arrest at G2/M in RL95-2 human endometrial cancer cells through activation of p53 and Chk1. Mol Cell Biochem 352(1–2):221–230. doi:10.1007/s11010-011-0757-x
32. Guo XH, Zhang N, Cui FD, Du B, Zhang ZZ (2009) An investigation on intestinal absorption of a new anticancer drug, 2-methoxyestradiol. Pharmazie 64(11):748–751
33. Guo X, Xing Y, Mei Q, Zhang H, Zhang Z, Cui F (2012) Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles. Anticancer Drugs 23(2):185–190. doi:10.1097/CAD.0b013e32834cf8d0
34. Guo X, Zhang X, Ye L, Zhang Y, Ding R, Hao Y, Zhao Y, Zhang Z, Zhang Y (2014) Inhalable microspheres embedding chitosan-coated PLGA nanoparticles for 2-methoxyestradiol. J Drug Target. doi:10.3109/1061186X.2013.878944
35. Gupta A, Kumar BS, Negi AS (2013) Current status on development of steroids as anticancer agents. J Steroid Biochem Mol Biol 137:242–270. doi:10.1016/j.jsbmb.2013.05.011
36. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K et al (2011) A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investig New Drugs 29(6):1465–1474. doi:10.1007/s10637-010-9455-x
37. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P (2004) Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53(3):209–219. doi:10.1007/s00280-003-0726-5
38. Hill LD, Ewens KG, Maher BS, York TP, Legro RS, Dunaif A, Strauss JF 3rd (2012) Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome. Mol Cell Endocrinol 350(1):72–77. doi:10.1016/j.mce.2011.11.022
39. Ho YT, Newman SP, Purohit A, Leese MP, Potter BV, Reed MJ (2003) The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis. J Steroid Biochem Mol Biol 86(2):189–196
40. Hoffman AR, Paul SM, Axelrod J (1979) Catecholestrogen synthesis and metabolism by human breast tumors in vitro. Cancer Res 39(11):4584–4587
41. Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C (2007) Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 16(3):481–489. doi:10.1158/1055-9965.EPI-06-0831
42. Huh JI, Qiu TH, Chandramouli GV, Charles R, Wiench M, Hager GL, Catena R et al (2007) 2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice. Endocrinology 148(3):1266–1277. doi:10.1210/en.2006-0964
43. Huober JB, Nakamura S, Meyn R, Roth JA, Mukhopadhyay T (2000) Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 48(4):1127–1137
44. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BV, Reed MJ (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90(4):932–937. doi:10.1038/sj.bjc.6601591
45. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD (2007) Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Investig New Drugs 25(1):41–48. doi:10.1007/s10637-006-9008-5
46. Jobe SO, Ramadoss J, Wargin AJ, Magness RR (2013) Estradiol-17beta and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites selectively stimulate production of prostacyclin in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension 61(2):509–518. doi:10.1161/HYPERTENSIONAHA.112.200717
47. Joubert A, Van Zyl H, Laurens J, Lottering ML (2009) C2- and C4-position 17beta-estradiol metabolites and their relation to breast cancer. Biocell 33(3):137–140
48. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S et al (2008) Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453(7198):1117–1121. doi:10.1038/nature06951
49. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M et al (2005) Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 90(2):1181–1188. doi:10.1210/jc.2004-0857
50. Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Branes J, Carvajal J, Lipkowitz S, Owen GI, Cuello MA (2008) 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts. Reprod Sci 15(9):878–894. doi:10.1177/1933719108324171
51. Kato S, Sadarangani A, Lange S, Villalon M, Branes J, Brosens JJ, Owen GI, Cuello M (2007) The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. Endocr Relat Cancer 14(2):351–368. doi:10.1677/ERC-07-0008
52. Krause D, Beck F, Agethen M, Blischke K (2014) Effect of catechol-O-methyltransferase-val158met-polymorphism on the automatization of motor skills—a post hoc view on an experimental data. Behav Brain Res 266C:169–173. doi:10.1016/j.bbr.2014.02.037
53. Kuo KL, Lin WC, Ho IL, Chang HC, Lee PY, Chung YT, Hsieh JT, Pu YS, Shi CS, Huang KH (2013) 2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells. PLoS One 8(8):e68703. doi:10.1371/journal.pone.0068703
54. Kurokawa A, Azuma K, Mita T, Toyofuku Y, Fujitani Y, Hirose T, Iwabuchi K et al (2007) 2-Methoxyestradiol reduces monocyte adhesion to aortic endothelial cells in ovariectomized rats. Endocr J 54(6):1027–1031
55. Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD (2007) Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci 96(7):1821–1831. doi:10.1002/jps.20837
56. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R (2010) Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 176(2):710–720. doi:10.2353/ajpath.2010.090513
57. Lee YH, Song GG (2014) COMT Val158Met and PPARgamma Pro12Ala polymorphisms and susceptibility to Alzheimer’s disease: a meta-analysis. Neurol Sci. doi:10.1007/s10072-014-1645-4
58. Lin G, Zhao J, Wu J, Andreevich OR, Zhang WH, Zhang Y, Yu L (2013) Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis. Genet Mol Res 12(4):6442–6453. doi:10.4238/2013.December.10.5
59. Lottering ML, Haag M, Seegers JC (1992) Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52(21):5926–5932
60. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363–375
61. Machado-Linde F, Pelegrin P, Sanchez-Ferrer ML, Leon J, Cascales P, Parrilla JJ (2012) 2-methoxyestradiol in the pathophysiology of endometriosis: focus on angiogenesis and therapeutic potential. Reprod Sci 19(10):1018–1029. doi:10.1177/1933719112446080
62. Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C (2009) Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 115(1):90–96. doi:10.1016/j.ygyno.2009.05.042
63. Min H, Ghatnekar GS, Ghatnekar AV, You X, Bu M, Guo X, Bu S, Shen B, Huang Q (2012) 2-Methoxyestradiol induced Bax phosphorylation and apoptosis in human retinoblastoma cells via p38 MAPK activation. Mol Carcinog 51(7):576–585. doi:10.1002/mc.20825
64. Mooberry SL (2003) New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15(6):425–430
65. Mosli HA, Tolba MF, Al-Abd AM, Abdel-Naim AB (2013) Catechol estrogens induce proliferation and malignant transformation in prostate epithelial cells. Toxicol Lett 220(3):247–258. doi:10.1016/j.toxlet.2013.05.002
66. Mueck AO, Seeger H (2010) 2-Methoxyestradiol—biology and mechanism of action. Steroids 75(10):625–631. doi:10.1016/j.steroids.2010.02.016
67. Mueck AO, Seeger H, Huober J (2004) Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol? Life Sci 75(10):1205–1210. doi:10.1016/j.lfs.2004.02.023
68. Mueck AO, Seeger H, Wallwiener D, Huober J (2004) Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations. Eur J Gynaecol Oncol 25(6):699–701
69. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BV, Reed MJ (2004) Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109(4):533–540. doi:10.1002/ijc.20045
70. Parada-Bustamante A, Orihuela PA, Rios M, Navarrete-Gomez PA, Cuevas CA, Velasquez LA, Villalon MJ, Croxatto HB (2007) Catechol-o-methyltransferase and methoxyestradiols participate in the intraoviductal nongenomic pathway through which estradiol accelerates egg transport in cycling rats. Biol Reprod 77(6):934–941. doi:10.1095/biolreprod.107.061622
71. Park SA, Na HK, Kim EH, Cha YN, Surh YJ (2009) 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res 69(6):2416–2424. doi:10.1158/0008-5472.CAN-08-2177
72. Perez-Sepulveda A, Espana-Perrot PP, Norwitz ER, Illanes SE (2013) Metabolic pathways involved in 2-methoxyestradiol synthesis and their role in preeclampsia. Reprod Sci 20(9):1020–1029. doi:10.1177/1933719113477483
73. Perez-Sepulveda A, Torres MJ, Valenzuela FJ, Larrain R, Figueroa-Diesel H, Galaz J, Nien JK, Serra R, Michea L, Illanes SE (2012) Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. Prenat Diagn 32(11):1053–1058. doi:10.1002/pd.3954
74. Qadan LR, Perez-Stable CM, Anderson C, D’Ippolito G, Herron A, Howard GA, Roos BA (2001) 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 285(5):1259–1266. doi:10.1006/bbrc.2001.5320
75. Quezada M, Diaz J, Henriquez S, Bravo ML, Aranda E, Oliva B, Villalon M et al (2010) 2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells. Horm Cancer 1(3):117–126. doi:10.1007/s12672-010-0019-5
76. Reiner T, de las Pozas A, Gomez LA, Perez-Stable C (2009) Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett 276(1):21–31. doi:10.1016/j.canlet.2008.10.026
77. Salih SM, Jamaluddin M, Salama SA, Fadl AA, Nagamani M, Al-Hendy A (2008) Regulation of catechol O-methyltransferase expression in granulosa cells: a potential role for follicular arrest in polycystic ovary syndrome. Fertil Steril 89(5 Suppl):1414–1421. doi:10.1016/j.fertnstert.2007.04.020
78. Salih SM, Kapur A, Albayrak S, Salama SA, Magness RR (2011) Pregnancy ameliorates the inhibitory effects of 2-methoxyestradiol on angiogenesis in primary sheep uterine endothelial cells. Reprod Sci 18(9):858–867. doi:10.1177/1933719111398149
79. Seeger H, Huober J, Wallwiener D, Mueck AO (2004) Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Horm Metab Res 36(5):277–280. doi:10.1055/s-2004-814480
80. Sibai B, Dekker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365(9461):785–799. doi:10.1016/S0140-6736(05)17987-2
81. Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Lee SR, Ko TH et al (2013) Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells. Exp Mol Med 45:e50. doi:10.1038/emm.2013.104
82. Sowers MR, Wilson AL, Kardia SR, Chu J, McConnell DS (2006) CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal. Am J Med 119(9 Suppl 1):S44–S51. doi:10.1016/j.amjmed.2006.07.006
83. Stander BA, Marais S, Vorster CJ, Joubert AM (2010) In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J Steroid Biochem Mol Biol 119(3–5):149–160. doi:10.1016/j.jsbmb.2010.02.019
84. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG (2005) 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res 11(5):1722–1732. doi:10.1158/1078-0432.CCR-04-1789
85. Teng Y, He C, Zuo X, Li X (2013) Catechol-O-methyltransferase and cytochrome P-450 1B1 polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 23(3):422–430. doi:10.1097/IGC.0b013e3182849e0d
86. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G (2009) Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15(4):1460–1465. doi:10.1158/1078-0432.CCR-08-1599
87. Theron AE, Nolte EM, Lafanechere L, Joubert AM (2013) Molecular crosstalk between apoptosis and autophagy induced by a novel 2-methoxyestradiol analogue in cervical adenocarcinoma cells. Cancer Cell Int 13(1):87. doi:10.1186/1475-2867-13-87
88. Thompson JM, Sonuga-Barke EJ, Morgan AR, Cornforth CM, Turic D, Ferguson LR, Mitchell EA, Waldie KE (2012) The catechol-O-methyltransferase (COMT) Val158Met polymorphism moderates the effect of antenatal stress on childhood behavioural problems: longitudinal evidence across multiple ages. Dev Med Child Neurol 54(2):148–154. doi:10.1111/j.1469-8749.2011.04129.x
89. Tian C, Liu L, Yang X, Wu H, Ouyang Q (2013) The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population. Tumour Biol. doi:10.1007/s13277-013-1387-6
90. Tsukamoto A, Kaneko Y, Yoshida T, Han K, Ichinose M, Kimura S (1998) 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun 248(1):9–12. doi:10.1006/bbrc.1998.8902
91. Verenich S, Gerk PM (2010) Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm 7(6):2030–2039. doi:10.1021/mp100190f
92. Visagie MH, Birkholtz LM, Joubert AM (2014) 17-beta-estradiol analog inhibits cell proliferation by induction of apoptosis in breast cell lines. Microsc Res Tech 77(3):236–242. doi:10.1002/jemt.22334
93. Visagie MH, Joubert AM (2010) The in vitro effects of 2-methoxyestradiol-bis-sulphamate on cell numbers, membrane integrity and cell morphology, and the possible induction of apoptosis and autophagy in a non-tumorigenic breast epithelial cell line. Cell Mol Biol Lett 15(4):564–581. doi:10.2478/s11658-010-0030-4
94. Visagie MH, Joubert AM (2012) 2-Methoxyestradiol-bis-sulphamate refrains from inducing apoptosis and autophagy in a non-tumorigenic breast cell line. Cancer Cell Int 12(1):37. doi:10.1186/1475-2867-12-37
95. Visagie M, Theron A, Mqoco T, Vieira W, Prudent R, Martinez A, Lafanechere L, Joubert A (2013) Sulphamoylated 2-methoxyestradiol analogues induce apoptosis in adenocarcinoma cell lines. PLoS One 8(9):e71935. doi:10.1371/journal.pone.0071935
96. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK (2001) Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension 37(2 Pt 2):645–650
97. Yang C, Shogren KL, Goyal R, Bravo D, Yaszemski MJ, Maran A (2013) RNA-dependent protein kinase is essential for 2-methoxyestradiol-induced autophagy in osteosarcoma cells. PLoS One 8(3):e59406. doi:10.1371/journal.pone.0059406
98. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L et al (2011) A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investig New Drugs 29(2):340–346. doi:10.1007/s10637-009-9383-9